191 related articles for article (PubMed ID: 9396394)
1. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Coze C; Hartmann O; Michon J; Frappaz D; Dusol F; Rubie H; Plouvier E; Leverger G; Bordigoni P; Béhar C; Beck D; Mechinaud F; Bergeron C; Plantaz D; Otten J; Zucker JM; Philip T; Bernard JL
J Clin Oncol; 1997 Dec; 15(12):3433-40. PubMed ID: 9396394
[TBL] [Abstract][Full Text] [Related]
2. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
3. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
6. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
[TBL] [Abstract][Full Text] [Related]
8. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
9. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
10. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
11. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?
Bernard JL; Philip T; Zucker JM; Frappaz D; Robert A; Margueritte G; Boilletot A; Philippe N; Lutz P; Roche H
J Clin Oncol; 1987 Dec; 5(12):1952-9. PubMed ID: 3681378
[TBL] [Abstract][Full Text] [Related]
12. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
14. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD
Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
[TBL] [Abstract][Full Text] [Related]
16. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
17. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
19. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
